Core Insights - The release of the "Clinical Application Expert Consensus on Lemborexant" marks a significant advancement in insomnia treatment in China, introducing Lemborexant as the first approved dual orexin receptor antagonist (DORA) in the country [1][2] - Insomnia affects 30% to 48% of the general population, significantly impacting quality of life and work performance, and is associated with various physical and mental health disorders [1] - The consensus aims to provide a scientific, practical, and systematic reference for the clinical diagnosis and treatment of insomnia, promoting standardized and individualized care in China [1][2] Group 1 - Lemborexant targets the sleep-wake system, offering a new pathway for insomnia treatment, moving from traditional broad sedation to precise regulation of sleep [1] - The consensus was developed by the Chinese Sleep Research Society in collaboration with various medical associations, based on the latest evidence and real-world data from China [1] - The innovative mechanism of Lemborexant provides a safer and more reliable option for patients requiring long-term management of insomnia due to its low dependency risk [1] Group 2 - The standardization of insomnia diagnosis and treatment is a key focus in the development of sleep medicine in China [2] - The consensus consolidates clinical experience and scientific evidence from domestic experts, guiding the rational use of Lemborexant and promoting high-quality insomnia care [2]